New investigations on retatruded, a dual agonist for GLP-1 and gastric inhibitory polypeptide, demonstrate promising findings in treating weight gain and type 2 diabetic condition. Initial evidence from clinical trials point to notable diminutions in body weight and enhanced glucose levels. Ongoi